Floatz logo

Cediranib

Undifferentiated Ovarian Carcinoma

Floatz Rating
BB69/100
Confidence
Indicative
v0.2
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT04739800CT.gov
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
—Active Not Recruiting———
NCT02923739CT.gov
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
—Terminated———
NCT02502266CT.gov
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
—Active Not Recruiting———
NCT02446600CT.gov
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
—Active Not Recruiting———
NCT02101775CT.gov
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
—Active Not Recruiting———
NCT01294293CT.gov
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
—Completed———
NCT00060359CT.gov
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Undifferentiated Ovarian Carcinoma

AssetSponsorPhaseRating
Cediranib (this asset)National Cancer Institute (NCI)P3BB · 69
CarboplatinNational Cancer Institute (NCI)P3BBB
AdriamycinNational Cancer Institute (NCI)P3BB
OlaparibNational Cancer Institute (NCI)P3BB
Cis-Diamminedichloroplatinum IiGynecologic Oncology GroupP3BB
NogitecanNational Cancer Institute (NCI)P2/3BB
DocetaxelNational Cancer Institute (NCI)P3BB
NivestimUniversity of WashingtonP2B
CyclophosphamideRoswell Park Cancer InstituteP2B

+24 more in the Undifferentiated Ovarian Carcinoma cohort

Other indications for Cediranib

IndicationSponsorPhaseRating
Gliosarcoma—P2BBB · 76
Metastatic Melanoma—P2BBB · 73
Adult Glioblastoma—P2BBB · 73

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Citation

Floatz Terminal. Cediranib in Undifferentiated Ovarian Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 13, 2026.
https://terminal.floatz.ai/assets/cediranib-undifferentiated-ovarian-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →